Seeger Weiss Reports Enrollment of 93% of Eligible Plaintiffs in VIOXX Settlement

Seeger Weiss LLP, announced today that 93 percent of eligible individuals have enrolled in the nationwide VIOXX settlement program first announced last November. Under the program, Merck has set aside $4.85 billion to compensate those claimants who suffered a heart attack, ischemic stroke, or sudden cardiac death while taking the drug. Seeger Weiss founding partner, […]

March 3, 2008

Cardiovascular Disease

Seeger Weiss LLP, announced today that 93 percent of eligible individuals have enrolled in the nationwide VIOXX settlement program first announced last November. Under the program, Merck has set aside $4.85 billion to compensate those claimants who suffered a heart attack, ischemic stroke, or sudden cardiac death while taking the drug.

Seeger Weiss founding partner, Chris Seeger, who was one of the chief negotiators of the settlement, has over the last several months joined other attorneys from Seeger Weiss and the Plaintiffs Negotiating Committee in meeting with lawyers from around the country to guide them through the enrollment process. Given his intimate knowledge of the proceedings, Mr. Seeger is not surprised by the settlement program’s success, stating: ‘While the size and scope of the program is one of the largest and most complex of any pharmaceutical litigation in history, the high rate of enrollment is unprecedented and represents a decisive endorsement of its fairness.’

Mr. Seeger and his firm have been one of the nation’s leaders in the Vioxx litigation since 2001, serving as lead counsel in two trials, resulting in a $47.5 million verdict for the plaintiff in that case, and Co-Lead Counsel for the Plaintiffs Steering Committee in the federal litigation before the Honorable E. Eldon Fallon. His partner, David Buchanan, serves as Co-Liaison Counsel in the New Jersey Vioxx Litigation.

Under the program, those claimants enrolling in the program by February 29, 2008, may qualify to receive an early interim payment of their settlement proceeds. Mr. Seeger and his co-counsel will continue to work with attorneys and the program administrators to facilitate enrollment.

Related News

October 3, 2023
Seeger Weiss Announces $425 Million Settlement with AstraZeneca in Proton-Pump Inhibitor Litigation

Seeger Weiss is pleased to announce a landmark $425 million settlement with AstraZeneca Pharmaceuticals in the Proton-Pump Inhibitor Products Liability Litigation. This significant achievement comes on behalf of thousands of consumers who suffered kidney injuries while using proton-pump inhibitor (“PPI”) medications. Founding partner Chris Seeger serves as co-lead counsel with Stephanie O’Connor of Douglas & […]

Read More
October 2, 2023
Seeger Weiss Founder Chris Seeger Awarded Law360 MVP for Product Liability

Seeger Weiss is pleased to announce that founding partner Chris Seeger was honored with a Law360 2023 MVP award for his product liability practice. This prestigious accolade serves as a testament to Chris’ unyielding commitment to holding corporations accountable and pursuing justice for consumers harmed by defective products. Over the course of the past year, […]

Read More
September 22, 2023
Seeger Weiss Represents City of Chicago in New PCB Lawsuit Against Monsanto

Earlier this week, the City of Chicago filed a lawsuit against Monsanto and other chemical companies seeking damages for widespread contamination of its waterways caused by Polychlorinated biphenyls (PCBs), highly toxic and dangerous chemical compounds known to accumulate in the human body and cause serious health effects. Plaintiffs allege that Monsanto intentionally misled the public […]

Read More